Mayo Clinic experimental dual-drug nanotherapy crosses the blood–brain barrier and improved survival in preclinical glioblastoma models
Peer-Reviewed Publication
Updates every hour. Last Updated: 25-May-2026 14:15 ET (25-May-2026 18:15 GMT/UTC)
Mayo Clinic researchers developed an experimental nanotherapy that delivers two cancer drugs directly to brain tumors, according to a study published in Nature Communications Medicine. The strategy extended survival in preclinical models of glioblastoma, the most aggressive form of brain cancer.
A new study develops and validates a nomogram to predict the need for continuous renal replacement therapy (CRRT) in patients with acute kidney injury (AKI) after lung transplantation. By integrating perioperative and early postoperative variables, this tool supports timely, individualized intervention, helping clinicians potentially reduce CRRT needs and improve patient outcomes in the complex post-lung transplant setting.
The diabetes drug, metformin, may mimic key benefits of exercise in prostate cancer patients, raising a molecule linked to weight and energy control even without activity. The finding suggests a new way to support metabolic health during hormone therapy, when patients often cannot exercise.
A population-based study in Japan published by Wiley online in CANCER has revealed a gradual increase in the rates of therapy-related acute myeloid leukemia in recent years, especially after breast cancer treatment.
Antivirals given for chronic hepatitis B include nucleos(t)ide analog monotherapy and pegylated interferon-alpha therapy, but the safety of interferon in patients with cirrhosis has been unclear. A study in Portal Hypertension and Cirrhosis analyzed data from two large Chinese cohorts, including 920 patients with compensated cirrhosis, and found that interferon therapy was not associated with a higher risk of serious complications, supporting its use with appropriate monitoring.
Researchers from Osaka Metropolitan University and Japan System Techniques Co., Ltd. evaluated the 2019 Osaka-Higashi Line station openings using a natural experiment and health insurance claims. While the overall rail-line effect was not significant, Shigino Station, a well-connected transfer hub, showed an estimated cumulative reduction of about JPY 62,500 per medically treated person over four years, highlighting that station connectivity and local context may determinewhether new stations deliver healthcare cost benefits.